Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Refractory and Relapsed Extranodal Natural Killer Cell/T-cell Lymphoma(EN): A Single-arm, Multicenter Phase I b/II Study(SCENT)

NCT03820596 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT03820596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03820596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Refractory and Relapsed Extranodal Natural Killer Cell/T-cell Lymphoma(EN): A Single-arm, Multicenter Phase I b/II Study(SCENT)
Lead sponsor
Huiqiang Huang
Phase
Phase 1/2
Overall status
Completed
Start date
March 29, 2019
Completion date
November 30, 2021
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

safety and efficacy